Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2024; 15(10): 2022-2035
Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2022
Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2022
Immunotherapy in type 1 diabetes: Novel pathway to the future ahead
Sayantan Ray, Department of Endocrinology, All India Institute of Medical Sciences, Bhuba
Rajan Palui, Department of Endocrinology, The Mission Hospital, Durgapur 713212, India
Author contributions: Ray S conceptualized the work, performed a literature search, supervised the writing, provided intellectual input, and critically revised the manuscript; Palui R supervised the literature search and writing, provided intellectual input, and critically revised the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rajan Palui, MBBS, MD, DM, Associate Specialist, Department of Endocrinology, The Mission Hospital, Bidhannagar, Durgapur 713212, India.
Received: June 8, 2024
Revised: July 23, 2024
Accepted: July 26, 2024
Published online: October 15, 2024
Processing time: 109 Days and 16.8 Hours
Revised: July 23, 2024
Accepted: July 26, 2024
Published online: October 15, 2024
Processing time: 109 Days and 16.8 Hours
Core Tip
Core tip: There has been a paradigm shift in research on type 1 diabetes (T1D) in the last decade. From managing the consequences of β cell death to prevention of β cell destruction, immunotherapy is showing the path forward. Recent regulatory approval of teplizumab in stage 2 of T1D marks the first significant advance in research of immunotherapy. In this Editorial, we briefly explore the recent developments and prospects in the field of immunotherapy in T1D encompassing antibody-based therapy, antigen-based therapy, and stem-cell-based immunotherapy.